English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Dott. Biagío Di Iorio, c/o Ospedale ‘D. Lentini’, viaXXVAprile, I-85045 Lauria (Italy) Dear Sir, We have already demonstrated [1] that initial CRF causes an increased urine excretion of Al even after an interruption of months of aluminum (Al) pharmacological intake. We studied 79 patients (36 M, 43 F), mean( ± SD) age 37.66 ± 15.15. They were distributed as follows: Group A: controls (15 M, 15 F); Group B: initial CRF, CrCl between 70 and30ml/min(10M, 18F); Group C: advanced CFR, CrCl between 30 and 5 ml/min (6 M, 7 F); Group D: most advanced CFR, CrCl between 12 and 5 ml/min in treatment on an artificial diet of essential amino acids and ketoanalogs (5 M, 3 F). All the patients interrupted their treatment to take the Al hydroxide for at least 3 months. The results (mean ± SD) are as follows: Al-s, μg/l: Group A: 5.65 ± 2.51; Group B: 6.01 ± 3.80; Group C: 5.78 ± 4.04; Group D: 5.67 ± 1.97. Al-s group A does not demonstrate statistical differences with Al-s of group B, C andD. Al-u, μg/die: Group A: 13.09 ± 10.07; Group B: 22.12 ± 17.25; Group C: 22.87 ± 24.46; Group D: 4.81 ± 1.49. Al-u group A p < 001 vs. group B, C andD. Urinary ratio Al/Cr * 10-3 mg was: Group A: 0.0105 ± 0.0096; Group B: 0.0301 ± 0.0367; Group C: 0.0351 ± 0.0427;

the nephron journals/nephron journals

Aluminum Urinary Excretion in Patients with Chronic Renal Failure in Treatment with Conservative Conventional Therapy and with Ketoanalogs: Research on Fasting Patients and after a Pharmacological Load